Dr. Reddy's Laboratories

Dr. Reddy’s and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

Saturday, October 17, 2020 - 11:44am

Earlier in September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.

Key Points: 
  • Earlier in September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.
  • As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddys upon regulatory approval in India.
  • This data will further strengthen the clinical development of Sputnik V vaccine in India.
  • Sputnik V is currently undergoing phase 3 clinical trial in Russia and the proposed number of subjects is 40,000.

Dr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020

Monday, October 12, 2020 - 1:51pm

The operator will provide instructions on asking questions before and during the call.

Key Points: 
  • The operator will provide instructions on asking questions before and during the call.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy’s Laboratories Joins Science Based Targets initiative (SBTi) and Sets 2030 GHG Emission Targets

Monday, October 5, 2020 - 10:27am

G V Prasad, Co-chairman and Managing Director, Dr. Reddys Laboratories, said, Continuous improvement in our environmental performance is a notable aspect of our sustainability journey.

Key Points: 
  • G V Prasad, Co-chairman and Managing Director, Dr. Reddys Laboratories, said, Continuous improvement in our environmental performance is a notable aspect of our sustainability journey.
  • We are delighted to join SBTi in taking a science-based approach to set our GHG emission reduction targets and accelerating our efforts to creating a positive impact on our planet.
  • In the Pharmaceutical & Biotech sector globally, 17 companies have successfully set their emission reduction targets affirming their pledge to mitigate climate change impacts.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market

Saturday, October 3, 2020 - 7:57am

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.
  • We are pleased to launch this generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating our continued commitment to bring affordable generic medicines to market for patients, says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddys Laboratories.
  • At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease.
  • Dr. Reddys Sapropterin Dihydrochloride Tablets, 100 mg are available in bottle count sizes of 120.

Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market

Thursday, October 1, 2020 - 9:08am

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA).
  • The Sensipar brand and generic market had U.S. sales of approximately $312 million MAT for the most recent twelve months ending in July 2020 according to IQVIA Health*.
  • Dr. Reddys Cinacalcet Tablets are available in 30 mg, 60 mg, and 90 mg tablets in a bottle count size of 30.
  • Sensipar is a trademark of Amgen Inc.
    About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market

Saturday, September 26, 2020 - 11:03am

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr.Reddys) today announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera (dimethyl fumarate) Delayed-Release Capsules, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr.Reddys) today announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera (dimethyl fumarate) Delayed-Release Capsules, approved by the U.S. Food and Drug Administration (USFDA).
  • The Tecfidera brand and generic market had U.S. sales of approximately $3.8 billion MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
  • Dr. Reddys Dimethyl Fumarate Delayed-Release Capsules are available in 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

Friday, September 25, 2020 - 8:16am

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).
  • Our ability to adequately supply Dexmedetomidine is important for patients as it is on the FDAs Drug Shortage list.
  • The Precedex in 0.9% Sodium Chloride Injection brand and generic market had U.S. sales of approximately $210 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
  • Dr. Reddys Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL clear glass vials, respectively.

Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company

Thursday, September 17, 2020 - 1:03pm

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID (lenalidomide) Capsules.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID (lenalidomide) Capsules.
  • Dr. Reddys is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.
  • Revlimid is a trademark of Celgene, a wholly owned subsidiary of Bristol Myers Squibb.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market

Thursday, September 17, 2020 - 6:52am

Dr. Reddys Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.

Key Points: 
  • Dr. Reddys Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.
  • The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is also indicated for the temporary relief of red eyes.
  • We are very excited to extend our strategic collaboration with Gland Pharma to bring these products to the market.
  • Dr. Reddys Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is available in a 2.5 mL bottle and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is available in a 5 mL bottle size.

RDIF and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India

Wednesday, September 16, 2020 - 11:26am

Upon regulatory approval in India, RDIF shall supply to Dr. Reddys 100 million doses of the vaccine.

Key Points: 
  • Upon regulatory approval in India, RDIF shall supply to Dr. Reddys 100 million doses of the vaccine.
  • The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic.
  • Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said, We are very pleased to partner with Dr. Reddys in India.
  • G V Prasad, Co-Chairman & Managing Director of Dr. Reddys Laboratories said, We are pleased to partner with RDIF to bring the vaccine to India.